Coherus BioSciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Coherus BioSciences, Inc. on November 27, 2023. The report discloses material events regarding the Company's oncology product, LOQTORZI (toripalimab-tpzi), specifically focusing on recent FDA approvals and the establishment of pricing.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The only financial data point disclosed is the pricing of a specific product.
- Wholesale Acquisition Cost (WAC): $8,892.03 per single-use vial for LOQTORZI.
Material Changes and Events
The filing highlights two significant developments regarding LOQTORZI:
- October 27, 2023 FDA Approval: The U.S. Food and Drug Administration approved LOQTORZI for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine. It was also approved as monotherapy for adults with recurrent, unresectable, or metastatic NPC who have progressed on or after platinum-containing chemotherapy.
- November 27, 2023 Pricing Announcement: The Company established the WAC for LOQTORZI at $8,892.03 per single-use vial.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or a discussion of specific risks and contingencies beyond the regulatory and commercial updates provided. No unusual items were reported.
Key Facts for Investor Verification
- Verify the commercial launch timeline and market access strategy for LOQTORZI following the FDA approval.
- Confirm the impact of the $8,892.03 WAC on reimbursement rates and net pricing after rebates.
- Review subsequent filings for sales data and revenue recognition related to the NPC indication.
- Monitor the competitive landscape for nasopharyngeal carcinoma treatments.